| Primary Peritoneal Carcinosarcoma studied in …STUDIED_INderived10 of 10 |
|---|
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 10 trials mapped (6 active) | — | — | Primary Peritoneal Carcinosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06580314Phase 3 · recruiting Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 10 trials mapped (6 active) | — | — | Primary Peritoneal Carcinosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04092270Phase 1 · active not recruiting A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 10 trials mapped (6 active) | — | — | Primary Peritoneal Carcinosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04919629Phase 2 · recruiting APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion · condition mapped ONTOLOGY_EXACT · 10 trials mapped (6 active) | — | — | Primary Peritoneal Carcinosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06483048Phase 1 · recruiting MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer · condition mapped CURATED_BROADER · 10 trials mapped (6 active) | — | — | Primary Peritoneal Carcinosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02364713Phase 2 · terminated MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 10 trials mapped (6 active) | — | — | Primary Peritoneal Carcinosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06639074Phase 2 · recruiting Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial · condition mapped ONTOLOGY_EXACT · 10 trials mapped (6 active) | — | — | Primary Peritoneal Carcinosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393751Phase 1/Phase 2 · withdrawn Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 10 trials mapped (6 active) | — | — | Primary Peritoneal Carcinosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02020707Phase 1 · completed Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers · condition mapped ONTOLOGY_EXACT · 10 trials mapped (6 active) | — | — | Primary Peritoneal Carcinosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03641287NA · terminated The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors · condition mapped ONTOLOGY_EXACT · 10 trials mapped (6 active) | — | — | Primary Peritoneal Carcinosarcoma | 1 | Observed | clinicaltrials | graph → |